ReviewEndocrine2009
Calcium-sensing receptor in cancer: good cop or bad cop?
Review in Endocrine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.The Journal of clinical endocrinology and metabolism · 2020Article
- Calcium-sensing receptor antagonist NPS-2143 suppresses proliferation and invasion of gastric cancer cells.Cancer gene therapy · 2020Article
- Intractable Generalized Epilepsy and Autosomal Dominant Hypocalcemia: A Case Report.Child neurology open · 2019Article
- The Calcium-Sensing Receptor and the Reproductive System.Frontiers in physiology · 2016Review
- Cross Talk between the Calcium-Sensing Receptor and the Vitamin D System in Prevention of Cancer.Frontiers in physiology · 2016Review
- Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.The American journal of clinical nutrition · 2015Article
- Cellular calcium dynamics in lactation and breast cancer: from physiology to pathology.American journal of physiology. Cell physiology · 2014Review
- High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor.Molecular cancer · 2014Article
- Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis.Anti-cancer agents in medicinal chemistry · 2013Review
- Calcium sensing receptor activation elevates proinflammatory factor expression in human adipose cells and adipose tissue.Molecular and cellular endocrinology · 2012Article
- Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.Molecular endocrinology (Baltimore, Md.) · 2012Review
- Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide.Case reports in oncology · 2012Article
- Calcium intake increases risk of prostate cancer among Singapore Chinese.Cancer research · 2010Article
- Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR.Pflugers Archiv : European journal of physiology · 2009Review
- The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells.Journal of experimental & clinical cancer research : CR · 2009Article
- Prostate cancer metastatic to bone has higher expression of the calcium-sensing receptor (CaSR) than primary prostate cancer.Receptors & clinical investigationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extracellular calcium-sensing receptor (CaR) is a versatile 'sensor' for di- and polycationic molecules in the body. CaR plays a key role in the defense against hypercalcemia by "sensing" extracellular calcium levels in the parathyroid and kidney, the key organs maintaining systemic calcium homeostasis. Although mutation of CaR gene has so far not been associated with any malignancy, aberrant functions of CaR have implications in malignant progression. One situation is loss of CaR expression, resulting in loss of growth suppressing effects of elevated extracellular Ca(2+) by CaR, reported in parathyroid adenoma and in colon carcinoma. Another situation is activation of CaR, resulting in increased production of parathyroid hormone-related peptide (PTHrP), a primary causal factor in hypercalcemia of malignancy and a contributor to metastatic processes involving bone. CaR signaling and effects have been studied in several cancers including ovarian cancers, gastrinomas, and gliomas in addition to comparatively detailed studies in breast, prostate, and colon cancers. Studies on H-500 rat Leydig cells, a xenotransplantable model of humoral hypercalcemia of malignancy has shed much light on the mechanisms of CaR-induced cancer cell growth and survival. Pharmacological agonists and antagonists of CaR hold therapeutic promise depending on whether activation of CaR is required such as in case of colon cancer or inactivating the receptor is required as in the case of breast- and prostate tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.